Navigation Links
Actonel Treats Hip Fractures In A Better Way Than Alendronate

New study shows that osteoporosis patients treated with Actonel are more likely to sustain when compared to alendronate. //These results were published today in the peer-reviewed journal Osteoporosis International after collecting data from 33,000 women with osteoporosis.

The study of 33,000 postmenopausal women showed that among patients newly prescribed one of the two most popular osteoporosis treatments, patients taking Actonel? (risedronate sodium) were approximately half as likely to sustain a hip fracture as those taking alendronate in the first year of treatment. 'The rapid onset of fracture reduction observed for risedronate in this study is consistent with results from randomised clinical trials of risedronate,' says Professor Pierre Delmas, study author, Universite Claude Bernard, Lyon.

'Earlier fracture protection means that fewer patients will suffer the devastating consequences of an osteoporotic fracture, helping to both preserve patients' quality of life and to reduce the economic burden of healthcare.'

The REAL (RisedronatE, ALendronate) retrospective cohort study included 33,830 women newly treated with once-weekly doses of either Actonel or alendronate in 'real-life' clinical practice. Results showed that at six months patients on Actonel had a 46% (p=0.02) lower incidence of hip fractures compared to patients on alendronate. At 12 months similar results were seen, with Actonel resulting in a 43% (p=0.01) greater reduction in risk of hip fracture versus alendronate. The two treatments were not compared on the basis of side effects in this study.

This study adds to the body of evidence from randomised controlled trials demonstrating that Actonel exerts an early onset of fracture protection, seen as early as six months for clinical vertebral fracture and nonvertebral fractures. No other bisphosphonate treatments for osteoporosis have been shown in clinical trials to reduce clinical fractures this early for pat ients. However, data are limited that compare therapies directly in the same study on the basis of fracture reduction - the clinically important endpoint in osteoporosis treatment.

'In the osteoporosis field it is unlikely that prospective, head-to-head clinical fracture trials will be conducted due to the large number of patients required to show a difference between two effective therapies,' said Professor Delmas. 'Large, comparative, retrospective analyses, like the REAL study, are one way to fill the knowledge gap and should be considered in the total body of evidence for a drug to optimise treatment decisions and enhance patient care.'

Currently 1.6 million hip fractures occur worldwide per year, accounting for approximately €104 billion in worldwide annual healthcare costs. Among those patients who suffer a hip fracture, approximately one in five will die within the following year and 40% will be unable to walk independently one year later.

Source-Eurekalert
SRI
'"/>




Related medicine news :

1. First head-to-head trials of once weekly Fosamax and Actonel therapies
2. Cyclosporin A Treats Leukemia Complications
3. Weight Reduction Surgery Also Treats Metabolic Syndrome
4. Chennai Hospital Treats Pakistani Blue Baby
5. Cocoa Treats: Chocolates, as a Health Investment? Chew on this!
6. New Gene Therapy Treats Diabetic Neuropathy
7. BBIC – A SOY-based Substance Treats Multiple Sclerosi
8. Cake Walk – Plum Treats Sell Like Hot Cakes During Christma
9. Common BP Drug Treats Muscular Dystrophy
10. Naltrexone also Treats Crohns Disease
11. Drug for Blood Pressure also Treats Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/11/2016)... ... February 11, 2016 , ... The ... among the top five firms in the “2015/2016 Best in KLAS: Software and ... Staffing. KLAS is a research and insights firm on a global mission to ...
(Date:2/11/2016)... FL (PRWEB) , ... February 11, 2016 , ... ... and advocates will discuss how to improve care by making data on heart ... heart disease. The Summit on Transparency and Public Reporting of Pediatric and Congenital ...
(Date:2/11/2016)... ... , ... In a new paper published in the latest ... J. Rohrich, and colleagues, examine and underscore the importance of upper lateral cartilage ... addressing this vital area. , The upper lateral cartilage in rhinoplasty, refers to ...
(Date:2/11/2016)... ... February 11, 2016 , ... veEDIS Clinical ... technology, with highly adaptable algorithms, has been updated to help Emergency Department physicians ... symptoms consistent with Zikas and a travel history to affected regions, or potential ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... trainer and author Ray Clarke poses a question as a challenge for his ... his book, "Being in the Being" (published by Partridge Singapore), Clarke explores the ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , February 11, 2016 Breast Cancer ... the Asia-Pacific (APAC) breast cancer market ... $3.4 billion by 2021, at a Compound Annual Growth Rate ... Asia-Pacific Markets to 2021 - states that the ... considerable expansion from $1.9 billion in 2014 to $3.4 billion ...
(Date:2/11/2016)... 11, 2016 --> ... new research report, titled "Sports Medicine Devices Market - Global ... 2019". According to the report, the global sports medicine devices ... 2013 to 2019, growing from a value of US$6.1 bn ... --> --> The global sports medicine devices ...
(Date:2/11/2016)... Jeffrey Zucker , vice president ... present at this year,s Summit for Clinical Operations Executives (SCOPE), ... Miami, FL. Zucker will discuss how sponsors ... supporting SCOPE,s "Improving Site Study Activation and Performance" portion of ... 25 at 11:05 a.m. --> ...
Breaking Medicine Technology: